News, Articles & Resources
Cancer Research and Cancer Support Articles
Pluvicto is used to treat adults with prostate cancer that has progressed and who have already received other anticancer treatments.
Xofigo is used to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone.
Lutathera® is a targeted drug therapy approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin. Learn More.
Marcia Schmidt, MD, gynecologic oncologist joins Florida Cancer Specialists & Research Institute in Palm Beach County.
Florida Cancer Specialists & Research Institute associate director Judy Wang, MD, is lead author of a manuscript on oral bacterial therapy to improve immunotherapy outcomes.
Dr. Hussein met with His Majesty King Abdullah II of Jordan to strengthen ties with Jordanian medical professionals working in the U.S.
Learn more about the causes, symptoms and treatment options for head and neck cancers of the mouth, throat, larynx, nose, sinuses or salivary glands.
Florida Cancer Specialists & Research Institute data leads to study on blood cancer being published in the Journal of Modern Economics.
FCS Top News Updates
March 3, 2026
FCS Signals Next Chapter of Growth With Planned Leadership Transition and Focus on Innovation
February 26, 2026
FCS Advances Genitourinary Cancer Research at American Society of Clinical Oncology 2026 GU Symposium
February 24, 2026
2026 Cancer Trends
February 13, 2026
FCS Celebrates Opening of New St. Petersburg Bayfront Location at Orlando Health Institute Square
Pluvicto™ Treatment: What You Can ExpectPluvicto is used to treat adults with prostate cancer that has progressed and who have already received other anticancer treatments.
Xofigo® Treatment: What You Can ExpectXofigo is used to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone.
Lutathera® Treatment: What You Can ExpectLutathera® is a targeted drug therapy approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin. Learn More.
FCS Expands Specialized Gynecologic Oncology ServicesMarcia Schmidt, MD, gynecologic oncologist joins Florida Cancer Specialists & Research Institute in Palm Beach County.
Judy Wang, MD is Lead Author of Manuscript Detailing Investigational Treatment to Improve Immunotherapy Outcomes for Patients with Advanced CancersFlorida Cancer Specialists & Research Institute associate director Judy Wang, MD, is lead author of a manuscript on oral bacterial therapy to improve immunotherapy outcomes.
Maen Hussein, MD Meets With King Abdullah II Ahead of UN General Assembly to Strengthen U.S.–Jordan Medical TiesDr. Hussein met with His Majesty King Abdullah II of Jordan to strengthen ties with Jordanian medical professionals working in the U.S.
Head and Neck CancerLearn more about the causes, symptoms and treatment options for head and neck cancers of the mouth, throat, larynx, nose, sinuses or salivary glands.
FCS Utilizes Proprietary Real-World Data in First Study of Treatment Response in Lower-Risk Myelodysplastic Syndrome Patients Treated with Erythropoiesis-Stimulating AgentsFlorida Cancer Specialists & Research Institute data leads to study on blood cancer being published in the Journal of Modern Economics.